Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis

Pediatric Blood and Cancer

Volumn 61, Issue 5, 2014, Pages 879-884

  Elalfy, Mohssen ^a   Wali, Yasser A ^b   Qari, Mohamad ^c   Al Damanhouri, Ghazi ^c   Al Tonbary, Youssef ^d   Yazman, Dilek ^e   Al Hawsawi, Zakaria ^f   Karakas, Zeynep ^g   Kilinc, Yurdanur ^h   Yesilipek, M Akif ⁱ   Badr, Mohamed ^j   Elsafy, Usama ^j   Salama, Mostafa ^k   Abdel Rahman, Yousryeia ^l   Shebl, Shebl ^m   Stilman, Anne ⁿ   Toiber Temin, Noemi ⁿ   Tricta, Fernando ⁿ  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^c KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^d MANSOURA UNIVERSITY CHILDREN S HOSPITAL   (Egypt)

^e Turkish Republic of Northtern Cyprus   (Cyprus)

^f MINISTRY OF HEALTH   (Saudi Arabia)

^g ISTANBUL UNIVERSITY   (Turkey)

^h CUKUROVA UNIVERSITY   (Turkey)

ⁱ AKDENIZ UNIVERSITY   (Turkey)

^j ZAGAZIG UNIVERSITY   (Egypt)

^k ALEXANDRIA UNIVERSITY   (Egypt)

^l ASSIUT UNIVERSITY   (Egypt)

^m TANTA UNIVERSITY   (Egypt)

ⁿ ApoPharma Inc   (Canada)

more..

Author keywords

Agranulocytosis; Deferiprone; Hemoglobinopathies; Neutropenia; Red blood cell disorders; Thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGRANULOCYTOSIS; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOIMMUNE HEMOLYTIC ANEMIA; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CHILL; CLINICAL PRACTICE; DISEASE COURSE; DRUG EFFICACY; DRUG INFORMATION; DRUG MONITORING; DRUG PACKAGING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GASTRITIS; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERTRANSAMINASEMIA; HYPESTHESIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDEROBLASTIC ANEMIA; SPHEROCYTOSIS; STOMACH DISEASE; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; VOMITING; YOUNG ADULT;

AGRANULOCYTOSIS; DEFERIPRONE; HEMOGLOBINOPATHIES; NEUTROPENIA; RED BLOOD CELL DISORDERS; THALASSEMIA;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PYRIDONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895731266     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24920     Document Type: Article

References (9)

1. Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol 2009; 122:155-164.
2. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107:3738-3744.
3. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107:3733-3737.
4. Masera N, Tavecchia L, Longoni DV, et al. Agranulocytosis due to deferiprone: A case report with cytomorphological and functional bone marrow examination. Blood Transfus 2011; 4:1-4.
5. Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: A multicentre study. Br J Haematol 2000; 108:305-312.
6. Food and Drug Administration, Oncologic Drugs Advisory Committee (ODAC) Briefing Document NDA # 21-825 Ferriprox® (deferiprone). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/OncologicDrugsAdvisoryCommittee/ucm271538.pdf
7. Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: Age, sex, smoking status, and ethnic differences. Ann Intern Med 2007; 146:486-492.
8. Wali Y, Shidhani AA, Daar S. Agranulocytosis in beta thalassemia major patients treated with oral iron chelating agent (deferiprone). Oman Med J 2008; 23:275-277.
9. ElAlfy MS, Sari TT, Lee CL, et al. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol 2010; 32:601-605.